Document is current

Article History

Received: 20 October 2024

Accepted: 11 January 2025

First Online: 16 January 2025

Declarations

:

: This study was approved by the Institutional Review Board Research Ethics Committee (IRBREC) of the Faculty of Medicine, Chulalongkorn University, Bangkok, and KCMH in October 2023 (IRB number 706/2023). The approval of retrieving retrospective data from electronic medical records (EMR) was made and informed consent was waived by IRBREC. All methods were carried out following relevant guidelines and regulations.

: Wanakorn Rattanawong receives speaker and advisory board honorarium from ZP therapeutics, DKSH Thailand, Pfizer Thailand, BL HUA, Viatris Thailand and Lundbeck; Prakit Anukoolwittaya receives speaker and advisory board honorarium from ZP therapeutics, DKSH Thailand, Pfizer Thailand, BL HUA, Akarin Hiransuthikul has no conflict of interest, Thanakit Pongpitakmetha receives speaker and advisory board honorarium from ZP therapeutics, Pfizer Thailand, and BL HUA, Auranee Trisataya is currently an employee at ZP therapeutics at the time of submission, Sekh Thanprasertsuk receives speaker and advisory board honorarium from ZP therapeutics, DKSH Thailand, Pfizer Thailand, BL HUA, Alan M. Rapoport serves as an advisor for AbbVie, Doctor Reddy’s, Satsuma; he is on the Speakers Bureau of AbbVie, Doctor Reddy’s and Teva Pharmaceutical Industries; he is Editor-in-Chief of Neurology Reviews and on the Editorial Board of CNS Drugs.